Replies to post #99383 on Biotech Values

[bxjwn9ru]

The uncertainty of the TEVA ANDA is what will keep the valuation reasonable and it should give caution to those who think it is a gift here.

Exactly my thoughts. Now if only the FDA would just reject TEVA's application we could get to $50 already.